Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$1.24 +12.7%	$1.10	$0.72 ▼ $6.94	$9.84M	0.24	739,857 shs	776,740 shs
BFRI Biofrontera	$0.66 +0.2%	$0.70	$0.54 ▼ $2.22	$6.23M	0.29	935,380 shs	87,053 shs
MYNZ Mainz Biomed	$1.62 -11.5%	$2.62	$1.60 ▼ $25.60	$5.57M	0.3	197,017 shs	120,049 shs
SXTC China SXT Pharmaceuticals	$1.73 -5.5%	$1.87	$0.95 ▼ $11.92	$27.38M	1.11	2.51 million shs	223,590 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	0.00%	-9.84%	-16.67%	-30.38%	-84.40%
BFRI Biofrontera	0.00%	+9.83%	+1.43%	-34.75%	-39.26%
MYNZ Mainz Biomed	0.00%	-11.81%	-25.00%	-60.48%	-92.68%
SXTC China SXT Pharmaceuticals	0.00%	-12.44%	+52.50%	-30.15%	-79.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCLI Brainstorm Cell Therapeutics	4.0783 of 5 stars	3.5	2.0	4.7	3.1	0.8	0.6
BFRI Biofrontera	2.3217 of 5 stars	3.5	3.0	0.0	1.8	0.0	1.3
MYNZ Mainz Biomed	2.6164 of 5 stars	3.3	5.0	0.0	0.7	0.8	1.3
SXTC China SXT Pharmaceuticals	0.3754 of 5 stars	0.0	3.0	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	3.00	Buy	$30.00	2,319.35% Upside
BFRI Biofrontera	3.00	Buy	$2.75	316.67% Upside
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	764.20% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, BCLI, MYNZ, and BFRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	BFRI Biofrontera	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $2.75

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.20) per share	N/A
BFRI Biofrontera	$38.00M	0.16	N/A	N/A	$3.16 per share	0.21
MYNZ Mainz Biomed	$893.99K	6.23	N/A	N/A	$10.82 per share	0.15
SXTC China SXT Pharmaceuticals	$1.82M	15.06	N/A	N/A	$30.46 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$17.19M	-$3.36	N/A	N/A	N/A	N/A	N/A	-528.56%	8/13/2025 (Estimated)
BFRI Biofrontera	-$20.13M	-$2.26	N/A	N/A	N/A	-36.31%	-565.73%	-96.64%	8/13/2025 (Estimated)
MYNZ Mainz Biomed	-$26.30M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	7/1/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, BCLI, MYNZ, and BFRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/1/2025	N/A	MYNZ Mainz Biomed	-$2.80	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	BCLI Brainstorm Cell Therapeutics	-$0.38	-$0.45	-$0.07	-$0.45	N/A	N/A
5/15/2025	Q1 2025	BFRI Biofrontera	-$0.14	-$0.47	-$0.33	-$0.47	$10.55 million	$8.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.05	0.05
BFRI Biofrontera	N/A	1.53	0.94
MYNZ Mainz Biomed	N/A	0.24	0.19
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
BFRI Biofrontera	10.08%
MYNZ Mainz Biomed	N/A
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
BFRI Biofrontera	1.20%
MYNZ Mainz Biomed	18.20%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	7.94 million	5.32 million	Optionable
BFRI Biofrontera	70	9.45 million	7.73 million	No Data
MYNZ Mainz Biomed	30	3.44 million	1.64 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable

SXTC, BCLI, MYNZ, and BFRI Headlines

Recent News About These Companies

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16 at 12:26 PM | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.com

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 26, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.com

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 2, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.com

China SXT Pharmaceuticals Inc (SXTC) Stock creates opportunities due to its volume and complexity

May 21, 2024 | bovnews.com

JAGX, BSGM and SXTC among mid-day movers

April 16, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, BCLI, MYNZ, and BFRI Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.24 +0.14 (+12.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 -0.01 (-1.21%)

As of 04:12 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Biofrontera NASDAQ:BFRI

$0.66 +0.00 (+0.15%)

As of 04:00 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Mainz Biomed NASDAQ:MYNZ

$1.62 -0.21 (-11.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 +0.04 (+2.78%)

As of 04:13 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.73 -0.10 (-5.46%)

Closing price 04:00 PM Eastern

Extended Trading

$1.79 +0.06 (+3.47%)

As of 04:11 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time